MAINZ BIOMED N.V. 8-K

What Happened
Mainz Biomed N.V. announced that on March 20, 2026 it received a letter from the Nasdaq Listing Qualifications Department stating the company did not meet Nasdaq’s $1.00 minimum closing bid price requirement (Nasdaq Rule 5550(a)(2)). Nasdaq determined the deficiency based on the closing bid price for 30 consecutive business days from February 5, 2026 through March 19, 2026. The company has been given a 180‑calendar‑day compliance period, until September 16, 2026, to regain compliance.

Key Details

• Letter dated March 20, 2026; deficiency based on 30 consecutive business days (Feb 5–Mar 19, 2026).
• Minimum required bid price: $1.00 per share; to regain compliance the Ordinary Shares must close at $1.00 or higher for at least 10 consecutive business days during the compliance period.
• Compliance period: 180 calendar days (until Sept 16, 2026).
• If not cured, the company may be eligible for an additional 180‑day cure period only if it meets Nasdaq’s market value of publicly held shares and other initial listing standards (except bid price) and provides written notice (a reverse stock split may be required); otherwise Nasdaq could move to delist. Shares remain listed and trading for now.

Why It Matters
A sustained failure to meet Nasdaq’s $1.00 minimum bid price could lead to delisting, which can reduce liquidity, limit investor access, and complicate the company’s ability to raise capital. The 180‑day compliance window gives Mainz Biomed time to cure the deficiency (for example by the stock rising above $1.00 for 10 straight business days or by corporate actions such as a reverse split), but there is no guarantee Nasdaq will grant additional time or that a cure will succeed. Investors should monitor the company’s stock price, company announcements about remediation plans (including any reverse split), and further Nasdaq correspondence.